CAMP4 Appoints Michael MacLean to Board

CAMP4 has appointed Michael MacLean to its Board of Directors, a move expected to bolster the company's strategic and financial leadership. This appointment comes as CAMP4 progresses its CMP-002 program toward a planned first-in-human Phase 1/2 clinical trial. MacLean's expertise is anticipated to be instrumental in guiding the company through its next phase of development and potential commercialization efforts.